NCT05233761View on ClinicalTrials.gov

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

July 2, 2022

Study Completion Date

July 2, 2022

Conditions
Insomnia
Interventions
DRUG

Defined CBD

300 mg CBD and 8 mg Terpenes administered as two small capsules.

DRUG

Placebo

Capsules that smell and look exactly like Defined CBD but contain no CBD or terpenes.

Trial Locations (1)

94107

Defined Research, San Francisco

Sponsors

Lead Sponsor

Defined Research
All Listed Sponsors
lead

Defined Research

INDUSTRY

NCT05233761 - Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia | Biotech Hunter | Biotech Hunter